Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -37,835 | -40,725 | -11,941 | -2,542 |
| Depreciation Amortization | 185 | 1,067 | 4 | 1 |
| Accounts payable and accrued liabilities | 1,195 | 1,390 | 472 | 52 |
| Other Working Capital | 622 | 666 | 1,142 | 209 |
| Other Operating Activity | 4,185 | 4,301 | 606 | 221 |
| Operating Cash Flow | $-31,648 | $-33,301 | $-9,717 | $-2,059 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -227 | -150 | -53 | N/A |
| Investing Cash Flow | $-227 | $-150 | $-53 | $N/A |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | N/A | 10,000 | N/A | N/A |
| Debt Issued | 17,500 | N/A | N/A | N/A |
| Common Stock Issued | 48,733 | 111,226 | 318 | 63 |
| Other Financing Activity | -348 | 63,875 | 12,993 | 3,927 |
| Financing Cash Flow | $65,885 | $185,101 | $13,311 | $3,990 |
| Beginning Cash Position | 157,147 | 5,497 | 1,956 | 25 |
| End Cash Position | 191,157 | 157,147 | 5,497 | 1,956 |
| Net Cash Flow | $34,010 | $151,650 | $3,541 | $1,931 |
| Free Cash Flow | ||||
| Operating Cash Flow | -31,648 | -33,301 | -9,717 | -2,059 |
| Capital Expenditure | -227 | -150 | -53 | N/A |
| Free Cash Flow | -31,875 | -33,451 | -9,770 | -2,059 |